For programs examining injury signals, dose response or mechanism in priority organs. A multi-organ study can compare risks across organs when needed.
R&D service
Human organoid safety and toxicology
Compare dose- and exposure-related responses in relevant normal-tissue organoids, using morphology, function and injury markers to investigate organ risk.
View imageKidney organoid safety evidence
Kidney identity, injury phenotype and molecular readouts
Kidney studies include identity and cisplatin molecular readouts in an H9-derived approach plus a doxorubicin acute-injury time course in human kidney organoids. Lung and other organs use organ-specific QC and endpoints selected for the project goal.
Study focus
Questions we can help answer
- 01Which injury signals emerge in the priority organ model?
- 02Which morphological, functional and molecular endpoints best characterize them?
- 03How do dose and exposure time shape injury and recovery?
STUDY APPROACH
Match the model and assays to your program
Select normal kidney, lung or GI organoids, or adjacent non-tumor liver models, based on candidate risk; confirm model identity and assay quality for each organ.
Combine viability, morphology, histology, injury markers and functional readouts suited to each organ.
Include vehicle, organ-appropriate injury controls, model QC and time points matched to the exposure design.
Compare injury signals across dose and exposure, then prioritize organs and mechanism or recovery studies for follow-up.
Study workflow
Select models and readouts around priority organ risks
We select normal-tissue models, exposure windows and complementary injury endpoints based on the candidate’s mechanism and known or anticipated organ risks.
Risk and exposure review
Review modality, target, expected exposure, known class risk and development stage.
Normal-tissue model QC
Confirm organ- and cell-type identity to establish a reliable baseline for drug-associated injury.
Dose, time and multimodal endpoints
Use dose, duration, positive and vehicle controls with morphology, viability, histology and molecular injury readouts.
Interpretation and next step
Compare in vitro injury trends and response windows, then prioritize signals for mechanistic or cross-model follow-up.
Study images and readouts
Drug-injury signals in kidney organoids
Nephron identity markers and drug-injury qPCR readouts combine structural and molecular evidence for selecting exposure conditions and follow-up injury endpoints.
View imageCisplatin-associated molecular changes: RT-qPCR compares KIM-1, H2AFX and inflammation- and stress-related gene expression in H9-derived kidney organoids.
TRiCBIO H9-derived kidney organoid cisplatin studyView the kidney organoid injury study
View imageInjury study | serial morphology: representative fields before exposure and at 24 and 48 hours provide temporal context for injury observation and downstream assay timing.
Study dataExpected study outputs
What you receive
Normal-tissue model and batch QC
Model identity, baseline morphology and batch-level QC results against the criteria agreed for the study.
Exposure and injury readouts
Dose and time conditions, controls, viability, morphology and molecular injury readouts.
Safety-study report
An integrated view of risk signals, study context and recommended follow-up studies.
Relevant model systems
Relevant model systems
Select normal-tissue models, exposure conditions and injury endpoints around each candidate’s priority organ risks. Compare doses, identify early risk signals and plan focused follow-up toxicology studies.
FAQ
Planning your study
Explore model selection, study planning and deliverables before your first discussion with our scientists.
Where can organoid safety studies support a drug-development program?
Normal-tissue organoids can support early candidate and dose comparison, identify organ-associated risk signals, and guide follow-up work on injury mechanisms, exposure windows or recovery. The results can help focus the organs, conditions and endpoints taken into subsequent in vivo, GLP or regulatory toxicology studies.
Which normal-tissue organoid models can be considered for a safety study?
Depending on the priority organ risk, a study can consider normal kidney, lung or gastrointestinal models, adjacent non-tumor liver organoids, or another relevant system. Model and assay selection is based on candidate mechanism, expected exposure, known class risks and the decision needed at this stage.
What information starts an organoid safety study, and what is typically delivered?
Start with the candidate modality and mechanism, expected exposure, priority organ risks and available safety findings. Deliverables can include model and batch QC, dose and time conditions, controls, viability and morphology results, molecular injury readouts, and a report placing the findings in study context with recommended follow-up. The exact deliverables are defined in the study plan.
PROJECT DISCUSSION
Plan a normal organoid safety study
Candidate modality, expected exposure, priority organ risks and available safety findings guide the choice of normal-tissue models, dosing and injury endpoints.